A method is provided for characterising and/or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.

Compounds for the prevention and treatment of cancer have a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist operatively linked to an antibody peptide operatively linked to a second binding peptide from an endostatin or plasminogen derived peptide sequence.

The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.